연세대학교 산학협력단; YONSEI UNIVERSITY;INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY;INDUSTRY-ACADEMIC COOPERATION FOUNDATION
发明人:
PARK, YONG BEOM,박용범,LEE, SANG WON,이상원,CHOI, DONG HOON,최동훈,PARK, SUNG HA,박성하,HONG, SUNG YU,홍성유
申请号：
KR1020130003850
公开号：
KR1020130083861A
申请日:
2013.01.14
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: The pharmaceutical composition for prevention or treatment of lupus nephritis including SRAGE as active ingredient is provided to show excellent effects of medical treatment in lupus nephritis by effectively reducing amount of proteinuria inside the textus renalis in immunocomplex deposition, and inside the concentrated blood serum claim -dsDNA antibody. CONSTITUTION: The pharmaceutical composition for prevention or treatment of lupus nephritis comprises the first sequence which unites ligand of receptor for advanced glycation end products: RAGE and soluble RAGE (sRAGE) as an active ingredient. The sRAGE of sequence listing first sequence obstructs bond between ligand of RAGE and RAGE. The sRAGE is combined with heavy chain of 7S antibody and Fc site of antibody The Fc site of antibody is Fc site of human immune globulin G1.본 발명은 sRAGE를 유효성분으로 포함하는 루푸스 신염(lupus nephritis)의 예방 또는 치료용 약제학적 조성물을 제공한다. 본 발명의 sRAGE는 면역글로블린 G의 중쇄(Heavy chain) 및 항체의 Fc 부위와 결합되어 있는 융합단백질로 제공되며, 본 발명의 조성물은 단백뇨의 양, 신장 조직 내 면역복합체 침착, 혈청 내 항-dsDNA 항체의 농도를 효과적으로 감소시킴으로써 루푸스 신염에서 우수한 치료효과를 나타낸다.
